Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands-0 ...
Copyright information: Taken from "Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands"http://www.resource-allocation.com/content/5/1/15Cost effectiveness and resource allocation : C/E 2007;5():15-15.Published online 22 Nov 2007PMCID:PMC2211743.se-case value were evaluated and these values are shown on both sides of the bars. All parameters refer to costs and are expressed in Euro price level 2006. TPV/r tipranavir with ritonavir. CPI/r comparator protease inhibitor with ritonavi... Mehr ...
| Verfasser: | |
|---|---|
| Dokumenttyp: | Figure |
| Erscheinungsdatum: | 2011 |
| Verlag/Hrsg.: |
figshare
|
| Schlagwörter: | Medicine |
| Sprache: | unknown |
| Permalink: | https://search.fid-benelux.de/Record/base-30413619 |
| Datenquelle: | BASE; Originalkatalog |
| Powered By: | BASE |
| Link(s) : | https://dx.doi.org/10.6084/m9.figshare.69208 |
Copyright information: Taken from "Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands"http://www.resource-allocation.com/content/5/1/15Cost effectiveness and resource allocation : C/E 2007;5():15-15.Published online 22 Nov 2007PMCID:PMC2211743.se-case value were evaluated and these values are shown on both sides of the bars. All parameters refer to costs and are expressed in Euro price level 2006. TPV/r tipranavir with ritonavir. CPI/r comparator protease inhibitor with ritonavir. HAART highly active antiretroviral therapy. iCER incremental cost effectiveness ratio. QALY quality adjusted life year. ...